药物基因组学
医学
血糖性
二甲双胍
养生
磺酰脲
2型糖尿病
噻唑烷二酮
2型糖尿病
重症监护医学
群众
糖尿病
内科学
药理学
内分泌学
哲学
认识论
作者
Zhichun Guo,Ronny Priefer
标识
DOI:10.1016/j.dsx.2021.102239
摘要
Type 2 diabetes mellitus (T2DM) is a prevalent disease with incidences increasing globally at a rapid rate. The goal of T2DM treatment is to control glucose levels and prevent the aggravation of glycemic symptoms.T2DM regimen include metformin as the first-line, with sulfonylurea, thiazolidinedione (TZD), GLP-1, DPP4I, and SGLT2 inhibitor as the second-line treatment options. However, even with a multitude of choices, patient-to-patient variability due to pharmacogenomic differences still prevail.This review aims to discuss the responses of the major T2DM medications influenced by pharmacogenomics and investigate improved personalized therapy for T2DM patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI